Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18716488 | 0.86 | HSD11B1 (0.39) | HSD11B1KMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL18686866 | 0.86 | HSD11B1 (0.39) | HSD11B1KMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL18716489 | 0.86 | HSD11B1 (0.39) | HSD11B1KMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL8759052 | 0.83 | HSD11B1 (0.39) | HSD11B1KMT2AMEN1TSHRSOAT1 | |
| SCHEMBL4170321 | 0.81 | MMP1 (0.39) | HSD11B1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL8615653 | 0.80 | L3MBTL1 (0.44) | KMT2ASOAT1SIGMAR1L3MBTL1LMNA | |
| SCHEMBL8615656 | 0.80 | L3MBTL1 (0.44) | KMT2ASOAT1SIGMAR1L3MBTL1LMNA | |
| SCHEMBL8871109 | 0.80 | L3MBTL1 (0.44) | KMT2ASOAT1SIGMAR1L3MBTL1LMNA | |
| SCHEMBL4183057 | 0.80 | GAA (0.48) | HSD11B1KMT2AMEN1TSHRSOAT1 | |
| SCHEMBL4181612 | 0.78 | HSD11B1 (0.36) | HSD11B1TSHRL3MBTL1LMNAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HSD11B1 1690/4885KMT2A 950/4885MEN1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.